SCHEMBL1499306

SCHEMBL1499306

CCN(CC)CCCNC(=O)c1cccc(Nc2cccc(NC(=O)c3cccc(OC)c3)c2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 4/20 0.57
RAB9A P51151 4/20 0.57
KCNK3 O14649 2/20 0.57
KCNK9 Q9NPC2 2/20 0.57
ALDH1A1 P00352 2/20 0.57
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
TP53 P04637 2/20 0.56
TSHR P16473 1/20 0.56
SIGMAR1 Q99720 1/20 0.54
BCHE P06276 1/20 0.54
RXFP1 Q9HBX9 1/20 0.54
MAPT P10636 2/20 0.53
GAA P10253 1/20 0.53
HTT P42858 2/20 0.51
POLB P06746 1/20 0.51
PKM P14618 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
MAPK14 Q16539 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29973702 1.00 NPC1 (0.57) NPC1RAB9AKCNK3KCNK9ALDH1A1
SCHEMBL1499350 0.95 KMT2A (0.60) NPC1RAB9AKCNK3KCNK9ALDH1A1
SCHEMBL12766934 0.93 BCHE (0.63) NPC1RAB9AKCNK3KCNK9ALDH1A1
SCHEMBL1499499 0.90 KMT2A (0.66) NPC1RAB9AKCNK3KCNK9ALDH1A1
SCHEMBL1499644 0.90 MEN1 (0.52) NPC1RAB9AKCNK3KCNK9ALDH1A1
SCHEMBL12767130 0.88 BCHE (0.59) NPC1RAB9AKCNK3KCNK9ALDH1A1
SCHEMBL1525896 0.85 MEN1 (0.60) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL1499416 0.83 KCNK3 (0.54) KCNK3ALDH1A1MEN1KMT2ASMN1; SMN2
SCHEMBL1499490 0.83 KMT2A (0.58) NPC1RAB9AALDH1A1MEN1KMT2A
SCHEMBL16963599 0.82 TDP1 (0.51) MEN1KMT2ASMN1; SMN2BCHEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9469804-B2 Foaming composition with wettability modifying and corrosion inhibitory properties for high temperature and ultra-high salinity Instituto Mexico del Petroleo (MX) 2016-10-18 US claimed
EP-2740781-B1 FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY INST MEXICANO DEL PETRÓLEO (MX) 2015-12-30 EP claimed
EP-2740781-A1 Foaming composition with wettability modifying and corrosion inhibitory properties for high temperature and ultra-high salinity Instituto Mexicano Del Petróleo (MX) 2014-06-11 EP claimed
US-20140151041-A1 FOAMING COMPOSITION WITH WETTABILITY MODIFYING AND CORROSION INHIBITORY PROPERTIES FOR HIGH TEMPERATURE AND ULTRA-HIGH SALINITY INSTITUTO MEXICANO DEL PETROLEO (MX) 2014-06-05 US claimed
JP-2011509280-A 2011-03-24 JP claimed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US claimed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP claimed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO claimed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO claimed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
EP-2235000-B1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NAT RECH SCIENT (FR) 2020-06-17 EP disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-05-19 US disclosed
US-10538485-B2 Compounds for use as therapeutic agents affecting P53 expression and/or activity ABIVAX (FR) 2020-01-21 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) 2011-03-03 US disclosed
EP-2235000-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES Centre National de la Recherche Scientifique (CNRS) (FR) 2010-10-06 EP disclosed
WO-2009087238-A9 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2010-02-25 WO disclosed
WO-2009087238-A2 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10654813-B2 Chemical molecules that inhibit the slicing mechanism for treating diseases resulting from splicing anomalies RBM17, RBM22, PRPF40A NPC1 589/4885RAB9A 3640/4885KCNK3 4541/4885
US-10538485-B2 Compounds for use as therapeutic agents affecting P53 expression and/or activity TP53, TP53BP1, BCOR NPC1 2190/4885RAB9A 615/4885KCNK3 4140/4885
US-20110053975-A1 CHEMICAL MOLECULES THAT INHIBIT THE SLICING MECHANISM FOR TREATING DISEASES RESULTING FROM SPLICING ANOMALIES RBM17, SF3B5, SF3B1 NPC1 922/4885RAB9A 4085/4885KCNK3 2948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.